Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine

F Hali; A Kerouach; H Alatawna; S Chiheb; H Lakhdar

doi:10.1111/ced.15007

Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine

Clin Exp Dermatol. 2022 Mar;47(3):611-613. doi: 10.1111/ced.15007. Epub 2021 Dec 8.

Authors

F Hali¹, A Kerouach¹, H Alatawna², S Chiheb¹, H Lakhdar¹

Affiliations

¹ Department of Dermatology and Venereology, Ibn Rochd University Hospital, Casablanca, Morocco.
² Center of Pathology, Ibn Zohr, Casablanca, Morocco.

Abstract

A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.

Publication types

Case Reports
Letter

MeSH terms

ChAdOx1 nCoV-19 / adverse effects*
Humans
Linear IgA Bullous Dermatosis / chemically induced*
Male
Middle Aged

Substances

ChAdOx1 nCoV-19